US 11471448
Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia
granted A61KA61K31/4409A61K9/48
Quick answer
US patent 11471448 (Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia) held by RedHill Biopharma Ltd. expires Mon Oct 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- RedHill Biopharma Ltd.
- Grant date
- Tue Oct 18 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 20
- CPC classes
- A61K, A61K31/4409, A61K9/48, A61P, A61P31/14